The companies claim this combined enterprise allows them to offer clients a full suite of sales and leadership training, and medical communications services for the domestic and global biopharmaceutical and medical device industries.
Steven Budd, CEO of New Jersey, US-based IMC, said: “This merger will create a formidable training company that offers the full continuum of services from multimedia curricula design and content development to elite skills training.
“In addition, IMC’s medical communications capabilities will be considerably enhanced by the addition of IC Axon’s team and their expertise in developing customised, engaging medical content.”
According to IMC and Axon, biopharmaceutical organisations are set to face a number of growing challenges in the coming years as companies scramble to keep up with training needs in pharmerging markets.
Executives from both companies say that by combining their capabilities they are better positioned to provide healthcare customers with “more comprehensive training and marketing solutions.”
General manager of Montreal, Canada-based IC Axon, Carole Gins, said she was excited by the prospect of a merger with IMC.
“We believe IMC’s unique dialogue training framework for enhancing sales and promotional impact” she said,” and their team of expert trainers and workshop facilitators provides the perfect complement to IC Axon’s core competency in the design, development and production of high-impact training programs.”
As part of the restructuring process Gins was appointed president of IMC.
IMC already runs two medical marketing companies under the auspices of the Informed Group.
The Peer Group, a medical marketing company offering small, group moderated forums, and RX Dialogue, a relationship marketing company working with pharma companies to help communicate disease state and treatment information to customers.
Both IMC and Axon insist that though they fully intend to pool resources, for the time being both will continue to operate out of their current locations.